Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA)

Historical Holders from Q4 2021 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
TRDA on Nasdaq
Shares outstanding
38,346,880
Price per share
$10.28
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
28,408,649
Total reported value
$164,766,258
% of total 13F portfolios
0%
Share change
-1,320,268
Value change
-$9,410,204
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
113
Price from insider filings
$9.98
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
5AM Ventures V, L.P. 11% $25,485,387 4,123,849 Kush Parmar 14 Nov 2025
ROCHE FINANCE LTD 6.9% $21,041,052 2,569,115 Roche Finance Ltd 31 Dec 2024
BlackRock, Inc. 5.3% $16,170,762 1,974,452 BlackRock, Inc. 31 Dec 2024
TCG Crossover GP I, LLC 5% $11,849,186 1,917,344 TCG Crossover GP I, LLC 19 Nov 2025
JANUS HENDERSON GROUP PLC 4% -27% $8,078,002 -$3,187,981 1,521,281 -28% JANUS HENDERSON GROUP PLC 30 Jun 2025
PRICE T ROWE ASSOCIATES INC /MD/ 0.9% -84% $2,091,051 -$12,800,322 360,526 -86% T. Rowe Price Associates, Inc. 30 Sep 2025
As of 30 Sep 2025, Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) has 113 institutional shareholders filing 13F forms. They hold 28,408,649 shares. of 38,346,880 outstanding shares (74%) .

Top 25 institutional shareholders own 67% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
BAKER BROS. ADVISORS LP 13% 4,865,819 0% 0.2% $28,221,750
MPM ASSET MANAGEMENT LLC 11% 4,381,062 0% 57% $25,410,160
5AM Venture Management, LLC 11% 4,256,379 -1.2% 9% $24,686,998
BlackRock, Inc. 5.3% 2,044,044 +1.1% 0% $11,855,456
VANGUARD GROUP INC 4.2% 1,604,225 -0.04% 0% $9,304,505
WELLINGTON MANAGEMENT GROUP LLP 2.5% 954,419 -10% 0% $5,535,630
MILLENNIUM MANAGEMENT LLC 2.2% 836,609 +391% 0% $4,852,332
StepStone Group LP 2% 761,277 0% 2.2% $4,415,407
GEODE CAPITAL MANAGEMENT, LLC 1.7% 645,119 +2.1% 0% $3,742,489
RENAISSANCE TECHNOLOGIES LLC 1.5% 594,300 +57% 0% $3,446,940
TCG Crossover Management, LLC 1.5% 584,955 0% 0.17% $3,392,739
STATE STREET CORP 1.3% 498,615 +0.56% 0% $2,891,967
DIMENSIONAL FUND ADVISORS LP 1% 394,279 -7% 0% $2,286,957
PRICE T ROWE ASSOCIATES INC /MD/ 0.94% 360,526 -86% 0% $2,092,000
MORGAN STANLEY 0.9% 346,756 +113% 0% $2,011,185
ROYCE & ASSOCIATES LP 0.9% 345,507 +55% 0.02% $2,003,941
CITADEL ADVISORS LLC 0.88% 335,741 +235% 0% $1,947,298
JACOBS LEVY EQUITY MANAGEMENT, INC 0.82% 315,810 +43% 0.01% $1,831,698
ACADIAN ASSET MANAGEMENT LLC 0.78% 297,943 +550% 0% $1,724,000
Qube Research & Technologies Ltd 0.75% 287,873 +115% 0% $1,669,663
NORTHERN TRUST CORP 0.66% 253,607 -16% 0% $1,470,920
JANE STREET GROUP, LLC 0.65% 247,516 +384% 0% $1,435,593
GOLDMAN SACHS GROUP INC 0.58% 222,336 +164% 0% $1,289,550
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.48% 185,259 -9% 0% $1,074,502
BNP PARIBAS FINANCIAL MARKETS 0.39% 148,212 0% 0% $859,630

Institutional Holders of Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 4,328 $44,493 +$2,869 1,028.21% 4
2025 Q3 28,408,649 $164,766,258 -$9,410,204 580% 113
2025 Q2 29,583,750 $198,790,015 -$4,881,405 672% 105
2025 Q1 30,241,830 $274,508,990 -$4,478,530 904% 110
2024 Q4 30,637,008 $529,755,083 +$9,629,187 1,729% 102
2024 Q3 30,099,996 $481,057,691 +$6,080,443 1,598% 98
2024 Q2 29,668,759 $422,811,056 +$52,061,074 1,425% 82
2024 Q1 26,027,444 $368,798,113 -$4,351,833 1,417% 76
2023 Q4 26,274,865 $396,535,081 +$3,015,345 1,509% 61
2023 Q3 26,035,608 $411,375,593 +$4,515,687 1,580% 55
2023 Q2 25,751,810 $389,878,048 +$13,506,404 1,514% 56
2023 Q1 24,900,040 $361,043,649 +$2,519,772 1,450% 53
2022 Q4 24,715,588 $334,178,958 +$2,434,290 1,352% 46
2022 Q3 24,516,893 $386,367,092 -$2,720,872 1,576.02% 32
2022 Q2 24,756,695 $301,567,417 -$13,034,791 1,218.01% 32
2022 Q1 25,847,504 $242,550,140 +$2,249,753 939.01% 46
2021 Q4 25,370,464 $433,824,000 +$422,462,101 1,711.99% 46